CPA: A Potential Drug Target for Cancer (P11266)

Target Name: Carboxypeptidase A

NCBI ID: P11266

Other Name(s): None

CPA: A Potential Drug Target for Cancer

Carboxypeptidase A (CPA) is an enzyme that is involved in the breakdown of a specific peptide chain on the surface of cancer cells. It is a potent predictor of cancer clinical outcome and has been identified as a potential drug target in cancer treatment.

CPA is a enzyme that is found in most tissues of the body, including the skin, hair, and nails. It is a member of the peptidases and Probability-checking enzyme (PBMC) superfamily and has a molecular weight of 34 kDa. CPA is typically expressed in high levels in cancer tissues and has been shown to be associated with cancer progression and poor prognosis.

One of the main functions of CPA is its role in the degradation of the peptide chain on the surface of cancer cells. This process is known as \"peptide degradation\" and is a critical step in the progression of cancer. Cancer cells are able to evade the immune system and continue to grow and multiply by producing new proteins, including those that are involved in their survival and proliferation. The degradation of these proteins by CPA helps to prevent cancer cells from evading the immune system and allows other immune cells to recognize and destroy them.

CPA has also been shown to play a role in the regulation of cell signaling pathways. For example, CPA has been shown to regulate the signaling pathway known as the TGF-β pathway, which is involved in cell growth, differentiation, and survival. This pathway is important for the development and maintenance of tissues and organs, including cancer.

In addition to its role in cell signaling pathways, CPA has also been shown to play a role in the regulation of cell adhesion. This process is important for the formation of tissues and organs and is critical for the development and maintenance of normal tissues. CPA has been shown to regulate the adhesion of cells to the surface of other cells and to play a role in the development of cancer.

CPA has also been shown to be involved in the regulation of cell migration. This process is important for the formation of tissues and organs and is critical for the development and maintenance of normal tissues. CPA has been shown to regulate the migration of cells to new environments and to play a role in the development of cancer.

CPA has also been shown to play a role in the regulation of cell apoptosis, which is the process by which cells die when they have reached a certain level of dysfunction or when they are no longer needed. This process is important for the removal of damaged or unnecessary cells and is a critical part of the immune response. CPA has been shown to regulate cell apoptosis and to play a role in the development of cancer.

CPA has also been shown to play a role in the regulation of tissue repair. This process is important for the formation of tissues and organs and is critical for the development and maintenance of normal tissues. CPA has been shown to regulate the repair of damaged tissues and to play a role in the development of cancer.

In conclusion, Carboxypeptidase A (CPA) is an enzyme that is involved in the breakdown of a specific peptide chain on the surface of cancer cells. It has been shown to be a potent predictor of cancer clinical outcome and has been identified as a potential drug target in cancer treatment. Further research is needed to fully understand the role of CPA in cancer biology and to develop effective treatments for this promising new drug target.

Protein Name: Carboxypeptidase A (nonspecified Subtype)

More Common Targets